Aranesp was one of Amgen’s best sellers for ... “Amgen leadership must make sure this doesn’t happen again.” The Wide Shot brings you news, analysis and insights on everything from ...

Any good news is great news for Amgen these days. Shares of Amgen surged 7.3% on Thursday after the biotech company announced that Aranesp, its blockbuster anemia drug, didn't increase mortality ...

See About archive blog posts. Procrit, Epogen and Aranesp, drugs that are used to stimulate red-blood-cell production in cancer patients made anemic by chemotherapy, increase the risk of venou ...

Amgen executives detailed their alleged Aranesp "overfill" kickback scheme in a set of PowerPoint slides and Excel spreadsheets, according to a lawsuit filed by the New York State Attorney General.

Opens in a new tab or window The biotech drug giant Amgen pled guilty Tuesday to promoting its blockbuster anemia drug darbepoetin alfa (Aranesp) for off-label dosing regimens, agreeing to pay ...

Darbepoetin alfa 10mcg/0.4mL, 25mcg/0.42mL, 40mcg/0.4mL, 60mcg/0.3mL, 100mcg/0.5mL, 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/mL; per prefilled syringe; for IV ...

Although these events have occurred predominantly in patients with chronic renal failure (CRF) who received darbepoetin alfa by subcutaneous injection ... related to use of Aranesp or Epogen ...

Florida and 48 other states said today they reached a $71 million settlement with Amgen Inc. resolving allegations that Amgen unlawfully promoted the medications Aranesp and Enbrel. Aranesp is ...

the trial showed no statistically significant difference in the frequency of blood transfusions in the population receiving placebo injections as opposed to those receiving Aranesp. Perlmutter ...

This time, it's $71 million to resolve allegations that it broke the rules when marketing its anemia drug Aranesp and anti-inflammatory blockbuster Enbrel, two of its best-selling meds.

Good news is hard to come by at Amgen. The company's slipped on Friday after the biotech giant announced that its fading anemia blockbuster Aranesp failed a late-stage study for breast cancer.